Semaglutide extended lifespan in old mice by 12.4% — but the real question is whether it slows aging or just fixes metabolic drift.
That’s the part worth arguing about.
In a new Nature study, researchers gave semaglutide to 20-month-old female mice that were already old — not diabetic, not massively obese, just aging.
Median lifespan went from 742 to 834 days.
That’s a real signal.
But there’s an immediate problem:
the mice on semaglutide also ate about 24% less.
So what actually extended life?
• the drug itself
• or plain old calorie restriction
That distinction matters.
Because on some outcomes, semaglutide looked a lot like calorie restriction:
• physical activity
• coordination
• muscle function
• endurance
But on others, it may have done better:
🟢 spatial memory
🟢 exploratory behavior
🟢 glucose control
🟢 signs of neurogenesis in the hippocampus
It also appeared to push several aging-related systems in a younger direction:
• less inflammation
• less cellular senescence
• less DNA damage
• better mitochondrial status
• better proteostasis
• a partial reversal of the age-related myeloid shift in blood stem cells
That’s why this is more interesting than another obesity headline.
The real possibility is that semaglutide may be acting not just as a weight-loss drug, but as a partial corrector of age-related metabolic and inflammatory drift.
Still, don’t oversell it.
Important caveats:
🟠 this was in mice
🟠 only females were tested
🟠 the lifespan gain was not fully disentangled from calorie restriction
🟠 834 days is not some impossible lifespan for this strain
So no, this is not proof that Ozempic is a longevity drug.
But it is one of the strongest hints yet that GLP-1 drugs may affect more than body weight — potentially touching the biology of aging itself.
🧬 The future of longevity will belong to people who measure their biology instead of guessing. Use my link for complete DNA sequencing and unlock 1000+ parameters about your body: https://shop.tellmegen.com/en?sca_ref=11848100.IoSIJUJzfNYC4
That’s the part worth arguing about.
In a new Nature study, researchers gave semaglutide to 20-month-old female mice that were already old — not diabetic, not massively obese, just aging.
Median lifespan went from 742 to 834 days.
That’s a real signal.
But there’s an immediate problem:
the mice on semaglutide also ate about 24% less.
So what actually extended life?
• the drug itself
• or plain old calorie restriction
That distinction matters.
Because on some outcomes, semaglutide looked a lot like calorie restriction:
• physical activity
• coordination
• muscle function
• endurance
But on others, it may have done better:
🟢 spatial memory
🟢 exploratory behavior
🟢 glucose control
🟢 signs of neurogenesis in the hippocampus
It also appeared to push several aging-related systems in a younger direction:
• less inflammation
• less cellular senescence
• less DNA damage
• better mitochondrial status
• better proteostasis
• a partial reversal of the age-related myeloid shift in blood stem cells
That’s why this is more interesting than another obesity headline.
The real possibility is that semaglutide may be acting not just as a weight-loss drug, but as a partial corrector of age-related metabolic and inflammatory drift.
Still, don’t oversell it.
Important caveats:
🟠 this was in mice
🟠 only females were tested
🟠 the lifespan gain was not fully disentangled from calorie restriction
🟠 834 days is not some impossible lifespan for this strain
So no, this is not proof that Ozempic is a longevity drug.
But it is one of the strongest hints yet that GLP-1 drugs may affect more than body weight — potentially touching the biology of aging itself.
🧬 The future of longevity will belong to people who measure their biology instead of guessing. Use my link for complete DNA sequencing and unlock 1000+ parameters about your body: https://shop.tellmegen.com/en?sca_ref=11848100.IoSIJUJzfNYC4
❤3
Seven new longevity signals just dropped — and most people will miss the pattern.
The big picture is simple:
Longevity is getting more programmable.
Not through one miracle drug — but through smarter control of metabolism, timing, sleep, hormones, movement, and risk management.
Translation:
what protects blood vessels may also protect the brain.
That’s less sexy than immortality marketing.
But it’s much closer to reality.
🧬 The winners in longevity will be the people who measure their biology instead of guessing. Use my link for complete DNA sequencing and unlock 1000+ parameters about your body: https://shop.tellmegen.com/en?sca_ref=11848100.IoSIJUJzfNYC4
The big picture is simple:
Longevity is getting more programmable.
Not through one miracle drug — but through smarter control of metabolism, timing, sleep, hormones, movement, and risk management.
Here’s what matters:
1. “Smart” probiotics that release GLP-1 when glucose rises
Researchers built engineered probiotic bacteria that can sense high glucose and then secrete GLP-1.
In mice and monkeys, they helped blunt glucose spikes and turned off when sugar normalized.
That’s a wild shift:
not just taking a drug — but deploying a living metabolic sensor.
Still early. Still safety questions.
But this is the kind of thing that makes future medicine look less like pills and more like programmable biology.
2. When you start eating may matter more than fasting window size
A new NHANES-based analysis suggests that delaying the first meal too late was associated with higher all-cause and cardiovascular mortality.
Compared with starting food around 7–8 AM, waiting until after noon was linked to a 29% higher risk of death.
Not proof of causation.
But it’s another hit against the lazy idea that “any fasting schedule is equally good.”
3. The “8 hours of sleep” rule is too dumb
A new review suggests the healthiest zone for many adults may be roughly 6.4 to 7.8 hours, not a universal 8.
The real goal is not worshipping one number.
It’s:
• enough sleep
• regular sleep
• stable circadian timing
4. HRT may reduce dementia risk in some women
In 183,000+ postmenopausal women from UK Biobank, menopausal hormone therapy was linked to about:
• 10% lower dementia risk overall
• 16% lower Alzheimer’s risk
The effect looked strongest in women with surgical menopause or lower lifetime estrogen exposure.
That adds fuel to the critical window idea:
timing matters.
5. Walkable neighborhoods may cut diabetes risk
Women with prior gestational diabetes who lived in more walkable areas had about a 15% lower risk of developing type 2 diabetes.
That’s a reminder people hate:
environment is a health intervention.
A walk-friendly neighborhood can quietly outperform a lot of motivation hacks.
6. The first wearable that tracks both glucose and ketones got FDA clearance
Libre Duo 10 Day can continuously measure:
• glucose
• ketones
This matters because metabolism is finally becoming observable in real time, not guessed from vibes.
For diabetics, this is clinically useful.
For biohackers, it opens a better window into metabolic flexibility.
7. Early statins after diabetes diagnosis may lower dementia risk
A Danish study of 130,000+ people with newly diagnosed type 2 diabetes found that starting statins in the first year was linked to about a 15% lower dementia risk over 10 years.
Translation:
what protects blood vessels may also protect the brain.
The real takeaway:
The future of longevity will not be built from one “anti-aging cure.”
It will come from stacking small advantages:
• better glucose control
• better meal timing
• better sleep rhythm
• smarter hormone use
• more walkable environments
• earlier cardiometabolic intervention
• better monitoring
That’s less sexy than immortality marketing.
But it’s much closer to reality.
🧬 The winners in longevity will be the people who measure their biology instead of guessing. Use my link for complete DNA sequencing and unlock 1000+ parameters about your body: https://shop.tellmegen.com/en?sca_ref=11848100.IoSIJUJzfNYC4
🤝2🥰1
“Zombie” cells don’t just sit there — they rewire their metabolism to keep inflammation on.
That’s the new Nature angle from Sanford Burnham Prebys / Mayo and collaborators.
Senescent cells leak mitochondrial signals.
Then a metabolic switch (around acetyl-CoA / DNA packaging) helps keep inflammatory SASP genes open.
🟢 In aging mice, hitting that metabolic step with CTPI-2 cut inflammation across tissues
🟢 Tissue function and healthspan markers improved
🟣 The immune leak from mitochondria was still there — but the inflammatory program got quieter
Important caveats:
🟠 mouse data
🟠 not a human therapy yet
🟠 “kill all zombies” is still too blunt — this is more like turning down their megaphone
🗒 Aging inflammation may be less “bad cells everywhere” and more bad metabolic settings that keep the alarm stuck on.
If you want a baseline on how your biology is drifting today → https://t.me/AgePilotBot
That’s the new Nature angle from Sanford Burnham Prebys / Mayo and collaborators.
Senescent cells leak mitochondrial signals.
Then a metabolic switch (around acetyl-CoA / DNA packaging) helps keep inflammatory SASP genes open.
🟢 In aging mice, hitting that metabolic step with CTPI-2 cut inflammation across tissues
🟢 Tissue function and healthspan markers improved
🟣 The immune leak from mitochondria was still there — but the inflammatory program got quieter
Important caveats:
🟠 mouse data
🟠 not a human therapy yet
🟠 “kill all zombies” is still too blunt — this is more like turning down their megaphone
🗒 Aging inflammation may be less “bad cells everywhere” and more bad metabolic settings that keep the alarm stuck on.
If you want a baseline on how your biology is drifting today → https://t.me/AgePilotBot
🔥2
The second of the seven has a name. Navier–Stokes.
For a century the equation of flowing water refused to say whether it always stays smooth, or whether it can tear itself open.
In 2003 Grigori Perelman closed the Poincaré conjecture. The first of seven. He declined the million, and the room.
Today OpenAI claims the second.
Not the Astra in your browser. A model they called significantly more capable than GPT-6 Astra. A thousand agents on the Euler cousin. Ten thousand on the full problem. 88 hours. About $15 million if you asked to run the same search.
They say no human opened the working trace.
The Clay Institute has not stamped it. A day earlier, Buckmaster and Alpöge published the stepping-stones, and a fight over credit had already begun. The coronation is announced. The priests have not nodded.
Still. Two of seven. The first took a man who walked away. The second, if it holds, was a machine that did not look up.
https://x.com/OpenAI/status/2097374640582668336
For a century the equation of flowing water refused to say whether it always stays smooth, or whether it can tear itself open.
In 2003 Grigori Perelman closed the Poincaré conjecture. The first of seven. He declined the million, and the room.
Today OpenAI claims the second.
Not the Astra in your browser. A model they called significantly more capable than GPT-6 Astra. A thousand agents on the Euler cousin. Ten thousand on the full problem. 88 hours. About $15 million if you asked to run the same search.
They say no human opened the working trace.
The Clay Institute has not stamped it. A day earlier, Buckmaster and Alpöge published the stepping-stones, and a fight over credit had already begun. The coronation is announced. The priests have not nodded.
Still. Two of seven. The first took a man who walked away. The second, if it holds, was a machine that did not look up.
https://x.com/OpenAI/status/2097374640582668336
🔥2
An AI-designed drug just made six independent aging clocks move younger — in humans.
Not a mouse study. Not another rapamycin remix. Rentosertib (Insilico): generative-AI TNIK inhibitor, aging biology in the brief from day one.
Phase IIa IPF trial. Serum proteomics. Six clocks (ProtAge, OrganAge, PAC + more).
All six: lower predicted biological age vs placebo. Peak: ~3–4 years younger at week 4 on 30 mg BID (up to ~6 on one clock).
Why this matters:
🟣 AI found the target
🟣 AI designed the molecule
🟣 aging clocks in the trial design, not bolted on later
🟣 best age-clock dose ≠ best lung dose — not just "lungs improved"
Caveats: 🟠 n=42 proteomic subset 🟠 every patient had IPF 🟠 clocks ≠ proof you slowed aging 🟠 healthy-volunteer data still missing
🗒 Real shift: disease trials can hunt geroprotection in parallel — years earlier than post-approval leftovers.
Baseline while science catches up → AgePilot
Source: Nature Biotechnology (Zhavoronkov et al., Sept 2026)
Not a mouse study. Not another rapamycin remix. Rentosertib (Insilico): generative-AI TNIK inhibitor, aging biology in the brief from day one.
Phase IIa IPF trial. Serum proteomics. Six clocks (ProtAge, OrganAge, PAC + more).
All six: lower predicted biological age vs placebo. Peak: ~3–4 years younger at week 4 on 30 mg BID (up to ~6 on one clock).
Why this matters:
🟣 AI found the target
🟣 AI designed the molecule
🟣 aging clocks in the trial design, not bolted on later
🟣 best age-clock dose ≠ best lung dose — not just "lungs improved"
Caveats: 🟠 n=42 proteomic subset 🟠 every patient had IPF 🟠 clocks ≠ proof you slowed aging 🟠 healthy-volunteer data still missing
🗒 Real shift: disease trials can hunt geroprotection in parallel — years earlier than post-approval leftovers.
Baseline while science catches up → AgePilot
Source: Nature Biotechnology (Zhavoronkov et al., Sept 2026)
🔥1
Partial epigenetic reprogramming just entered a human trial.
Not a mouse. Not a press-kit fantasy.
Life Biosciences dosed the first participant with ER-100 — OSK (OCT4, SOX2, KLF4), no c-MYC.
One eye. Glaucoma or NAION. AAV into retinal ganglion cells.
Doxycycline flips the switch for 56 days.
Why the eye:
🟢 local delivery you can image
🟢 pressure drugs don’t restore lost neurons
🟢 2020 Nature mouse work restored vision-linked function + younger epigenetic signatures
What this is NOT:
🟠 human age reversal
🟠 whole-body rejuvenation
🟠 proof anyone sees better yet
Primary endpoint: safety. Up to 18 people. Years of follow-up.
🗒 Threshold most people will miss: Yamanaka-style partial reprogramming is no longer only an animal paper — it’s a clinical protocol.
Know your biology while the trial runs → https://shop.tellmegen.com/en?sca_ref=11848100.IoSIJUJzfNYC4
Source: Life Biosciences / NCT07290244 (first dose Jun 2026)
Not a mouse. Not a press-kit fantasy.
Life Biosciences dosed the first participant with ER-100 — OSK (OCT4, SOX2, KLF4), no c-MYC.
One eye. Glaucoma or NAION. AAV into retinal ganglion cells.
Doxycycline flips the switch for 56 days.
Why the eye:
🟢 local delivery you can image
🟢 pressure drugs don’t restore lost neurons
🟢 2020 Nature mouse work restored vision-linked function + younger epigenetic signatures
What this is NOT:
🟠 human age reversal
🟠 whole-body rejuvenation
🟠 proof anyone sees better yet
Primary endpoint: safety. Up to 18 people. Years of follow-up.
🗒 Threshold most people will miss: Yamanaka-style partial reprogramming is no longer only an animal paper — it’s a clinical protocol.
Know your biology while the trial runs → https://shop.tellmegen.com/en?sca_ref=11848100.IoSIJUJzfNYC4
Source: Life Biosciences / NCT07290244 (first dose Jun 2026)
🔥1
An Anthropic researcher just quit. His punchline is not funny — but our angle is.
Jacob Coxon left Anthropic after three years of pretraining work at OpenAI and Anthropic.
His claim: both labs are racing to self-improving superintelligence and “gambling with our lives.”
Insider belief, he says: AI could kill us all by the end of the decade. Not a marketing stunt.
Anthropic’s alignment lead Evan Hubinger replied in public: yes, they earnestly believe AI could kill all humans — and he puts his own odds at >10% this decade. No clear plan for superintelligence alignment yet.
🟠 private fear, public race
🟠 hubris: “we must get there first because others won’t be careful”
🟠 longevity tip from the same news: if the machines win, NAD+ and VO₂max become… optional
🗒 Keep stacking healthspan. Also notice when the people building the future say the future might not include you.
Sources: Coxon on X; Hubinger; TechCrunch / WSJ, 9 Sep 2026
Jacob Coxon left Anthropic after three years of pretraining work at OpenAI and Anthropic.
His claim: both labs are racing to self-improving superintelligence and “gambling with our lives.”
Insider belief, he says: AI could kill us all by the end of the decade. Not a marketing stunt.
Anthropic’s alignment lead Evan Hubinger replied in public: yes, they earnestly believe AI could kill all humans — and he puts his own odds at >10% this decade. No clear plan for superintelligence alignment yet.
🟠 private fear, public race
🟠 hubris: “we must get there first because others won’t be careful”
🟠 longevity tip from the same news: if the machines win, NAD+ and VO₂max become… optional
🗒 Keep stacking healthspan. Also notice when the people building the future say the future might not include you.
Sources: Coxon on X; Hubinger; TechCrunch / WSJ, 9 Sep 2026
🔥1
Your gut may predict inflammaging better than your birthday.
Not a probiotic ad. Nature Communications — DanFunD cohort, 1,199 adults aged 20–72.
Paired fecal microbiota + 30 plasma cytokines + physiology.
The punchline:
🟢 microbiota explained more variance than age for 97% of cytokines
🟢 and 84% of physiological measures
🟣 Bacteroides 2 enterotype: inflammaging-like profile up to ~37 years earlier
🟣 same pattern → higher future disease risk (HR ~1.21)
🟢 high-diversity enterotype → lower inflammation, lower risk
Caveats:
🟠 association, not a probiotic prescription
🟠 enterotypes are messy labels
🟠 Denmark cohort — not “your stool test = destiny”
🗒 Chronological age is a weak proxy for inflammatory tone. Your microbial community may be a louder — and more modifiable — signal.
Baseline while science catches up → https://t.me/AgePilotBot?start=ref_134163805
Source: Eriksen et al., Nature Communications, 8 Sep 2026
Not a probiotic ad. Nature Communications — DanFunD cohort, 1,199 adults aged 20–72.
Paired fecal microbiota + 30 plasma cytokines + physiology.
The punchline:
🟢 microbiota explained more variance than age for 97% of cytokines
🟢 and 84% of physiological measures
🟣 Bacteroides 2 enterotype: inflammaging-like profile up to ~37 years earlier
🟣 same pattern → higher future disease risk (HR ~1.21)
🟢 high-diversity enterotype → lower inflammation, lower risk
Caveats:
🟠 association, not a probiotic prescription
🟠 enterotypes are messy labels
🟠 Denmark cohort — not “your stool test = destiny”
🗒 Chronological age is a weak proxy for inflammatory tone. Your microbial community may be a louder — and more modifiable — signal.
Baseline while science catches up → https://t.me/AgePilotBot?start=ref_134163805
Source: Eriksen et al., Nature Communications, 8 Sep 2026
🔥1
Cut the calories — and the genome takes fewer hits.
Not a longevity influencer tip. Cell, online now (9 Sep 2026).
Mice at −30% calories. High-fidelity duplex sequencing across liver, kidney, hepatocytes, cerebellar neurons.
What moved:
🟢 fewer substitutions genome-wide
🟢 fewer insertions/deletions
🟢 SBS5 — the quiet mutational process behind most mammalian mutations — dialed down
🟣 strongest drop in transcriptionally quiet DNA
🟣 liver felt it more than kidney or brain
Why it matters:
🟠 genomic instability is a hallmark of aging — diet just touched it
🟠 this is mice, not your intermittent-fasting protocol
🟠 extreme CR is hard and risky in humans — the goal is the mechanism, not the starvation
🗒 Lifespan links to diet were old news. Genome-wide mutation load as a modifiable aging axis is the new punchline.
Source: Grońska-Pęski, Evrony et al., Cell 2026 · DOI 10.1016/j.cell.2026.08.013
Not a longevity influencer tip. Cell, online now (9 Sep 2026).
Mice at −30% calories. High-fidelity duplex sequencing across liver, kidney, hepatocytes, cerebellar neurons.
What moved:
🟢 fewer substitutions genome-wide
🟢 fewer insertions/deletions
🟢 SBS5 — the quiet mutational process behind most mammalian mutations — dialed down
🟣 strongest drop in transcriptionally quiet DNA
🟣 liver felt it more than kidney or brain
Why it matters:
🟠 genomic instability is a hallmark of aging — diet just touched it
🟠 this is mice, not your intermittent-fasting protocol
🟠 extreme CR is hard and risky in humans — the goal is the mechanism, not the starvation
🗒 Lifespan links to diet were old news. Genome-wide mutation load as a modifiable aging axis is the new punchline.
Source: Grońska-Pęski, Evrony et al., Cell 2026 · DOI 10.1016/j.cell.2026.08.013
❤1
Ozempic’s cousin just bought old mice ~100 extra days.
Not a weight-loss ad. Nature (2 Sep 2026) — UC Berkeley / NIA: late-life semaglutide in healthy female mice.
Setup:
🟢 start at 20 months (~human 60s)
🟢 daily GLP-1RA until death → median lifespan ≈ +100 days (~12%)
🟣 vs matched 24% calorie restriction: drug kept memory, curiosity, and blood sugar better
🟣 metabolic rate stayed up — CR slowed it down
Why it’s juicy:
🟠 looks like a CR mimetic… plus extras that aren’t “just eat less”
🟠 hallmarks dialed down: inflammation, weak regeneration
🟠 female mice only — no human longevity claim yet
🗒 This morning: CR cut genome mutations. This afternoon: a GLP-1RA stretches late life in mice. Same axis, different tool.
TellMeGen — DNA context for the habits you keep stacking.
Source: Feng, Chen et al., Nature 2026 · DOI 10.1038/s41586-026-10940-7
Not a weight-loss ad. Nature (2 Sep 2026) — UC Berkeley / NIA: late-life semaglutide in healthy female mice.
Setup:
🟢 start at 20 months (~human 60s)
🟢 daily GLP-1RA until death → median lifespan ≈ +100 days (~12%)
🟣 vs matched 24% calorie restriction: drug kept memory, curiosity, and blood sugar better
🟣 metabolic rate stayed up — CR slowed it down
Why it’s juicy:
🟠 looks like a CR mimetic… plus extras that aren’t “just eat less”
🟠 hallmarks dialed down: inflammation, weak regeneration
🟠 female mice only — no human longevity claim yet
🗒 This morning: CR cut genome mutations. This afternoon: a GLP-1RA stretches late life in mice. Same axis, different tool.
TellMeGen — DNA context for the habits you keep stacking.
Source: Feng, Chen et al., Nature 2026 · DOI 10.1038/s41586-026-10940-7
Senescent cells wear an immune cloak — and it has a name: PD-L2.
Cell Metabolism (online today, 10 Sep 2026) — Cedars-Sinai / Kirkland lab.
What’s new:
🟢 PD-L2 rises on senescent cells and with aging
🟢 soluble PD-L2 climbs in blood; senolytics can knock the high-PD-L2 cells down in humans
🟢 PD-L2 knockout mice keep fewer zombies — better insulin sensitivity + grip strength
🟣 anti-PD-L2 restored insulin sensitivity in old wild-type mice
Why it bites:
🟠 senescent cells aren’t just “stuck” — they may actively hide from clearance
🟠 this is still mostly mouse + biomarker evidence, not a clinic drug
🟠 checkpoint blockade has real immune risks — don’t DIY oncology tools for longevity
🗒 Senolytics kill. Immune surveillance unmasks. PD-L2 sits at that intersection.
Source: Chaib, Kirkland et al., Cell Metabolism 2026 · DOI 10.1016/j.cmet.2026.08.014
Cell Metabolism (online today, 10 Sep 2026) — Cedars-Sinai / Kirkland lab.
What’s new:
🟢 PD-L2 rises on senescent cells and with aging
🟢 soluble PD-L2 climbs in blood; senolytics can knock the high-PD-L2 cells down in humans
🟢 PD-L2 knockout mice keep fewer zombies — better insulin sensitivity + grip strength
🟣 anti-PD-L2 restored insulin sensitivity in old wild-type mice
Why it bites:
🟠 senescent cells aren’t just “stuck” — they may actively hide from clearance
🟠 this is still mostly mouse + biomarker evidence, not a clinic drug
🟠 checkpoint blockade has real immune risks — don’t DIY oncology tools for longevity
🗒 Senolytics kill. Immune surveillance unmasks. PD-L2 sits at that intersection.
Source: Chaib, Kirkland et al., Cell Metabolism 2026 · DOI 10.1016/j.cmet.2026.08.014
Six aging clocks. One AI-designed drug. Younger blood proteomes.
Nature Biotechnology (7 Sep 2026) — Phase 2a rentosertib (Insilico), the generative-AI TNIK inhibitor for IPF.
What moved:
🟢 six independent proteomic aging clocks all trended younger on drug vs placebo
🟢 peak ~3–4 years younger at week 4 (30 mg BID); up to ~6 on one clock
🟢 FVC improved too — but best lung dose ≠ strongest clock signal
🟣 senomorphic shift: less senescence/fibrosis proteins, remapped growth-factor paths
Caveats:
🟠 n=42, company-sponsored, exploratory biomarkers — not a lifespan trial
🟠 clocks can’t fully untangle less fibrosis from slower aging
🟠 don’t DIY an IPF investigational for “bio-age”
🗒 Put aging endpoints inside disease trials — geroprotection may show up years earlier.
AgePilot — habits that move the healthspan dial.
Source: Zhavoronkov et al., Nat Biotechnol 2026 · DOI 10.1038/s41587-026-03286-y
Nature Biotechnology (7 Sep 2026) — Phase 2a rentosertib (Insilico), the generative-AI TNIK inhibitor for IPF.
What moved:
🟢 six independent proteomic aging clocks all trended younger on drug vs placebo
🟢 peak ~3–4 years younger at week 4 (30 mg BID); up to ~6 on one clock
🟢 FVC improved too — but best lung dose ≠ strongest clock signal
🟣 senomorphic shift: less senescence/fibrosis proteins, remapped growth-factor paths
Caveats:
🟠 n=42, company-sponsored, exploratory biomarkers — not a lifespan trial
🟠 clocks can’t fully untangle less fibrosis from slower aging
🟠 don’t DIY an IPF investigational for “bio-age”
🗒 Put aging endpoints inside disease trials — geroprotection may show up years earlier.
AgePilot — habits that move the healthspan dial.
Source: Zhavoronkov et al., Nat Biotechnol 2026 · DOI 10.1038/s41587-026-03286-y
Turn off growth-hormone signaling at midlife — mice live longer.
Aging Cell (5 Sep 2026) — Duran-Ortiz / Kopchick: inducible Ghr knockout at 12 months (roughly human midlife). Not a lifelong dwarf model.
What moved:
🟢 lifespan up in both sexes (log-rank: ♂ p=0.0085, ♀ p=0.0264)
🟢 females: ~8% median (1003 vs 929 days); max lifespan +12%
🟢 males: ~7% median trend; better insulin sensitivity + preserved bone/strength signals
🟣 classic GH resistance: lower IGF-1, higher GH — without wrecking adult growth
Caveats:
🟠 mice + genetic KO, not a human drug trial
🟠 more fat / less lean later — weird body-comp tradeoff
🟠 total GH block ≠ safe DIY; FDA-approved antagonist pegvisomant still untested for aging
🗒 Congenital GH/IGF-1 cuts already win longevity contests. This paper asks the clinic-relevant question: is midlife late enough — and answers yes, in mice.
Source: Duran-Ortiz et al., Aging Cell 2026 · DOI 10.1111/acel.70695
Aging Cell (5 Sep 2026) — Duran-Ortiz / Kopchick: inducible Ghr knockout at 12 months (roughly human midlife). Not a lifelong dwarf model.
What moved:
🟢 lifespan up in both sexes (log-rank: ♂ p=0.0085, ♀ p=0.0264)
🟢 females: ~8% median (1003 vs 929 days); max lifespan +12%
🟢 males: ~7% median trend; better insulin sensitivity + preserved bone/strength signals
🟣 classic GH resistance: lower IGF-1, higher GH — without wrecking adult growth
Caveats:
🟠 mice + genetic KO, not a human drug trial
🟠 more fat / less lean later — weird body-comp tradeoff
🟠 total GH block ≠ safe DIY; FDA-approved antagonist pegvisomant still untested for aging
🗒 Congenital GH/IGF-1 cuts already win longevity contests. This paper asks the clinic-relevant question: is midlife late enough — and answers yes, in mice.
Source: Duran-Ortiz et al., Aging Cell 2026 · DOI 10.1111/acel.70695
Why is human longevity still a billionaire blind spot?
NFX Bio / Longevity.Technology: science is at an inflection — reprogramming, organs, delivery, AI discovery, diagnostics. Tech tree mapped. Capital is not.
Aging is the #1 disease risk factor, yet under 0.5% of NIH funding. Many ultra-wealthy stay away: burned by clinics, doubt aging is fixable, assume wealth buys the cure later, or fear looking vain.
🟢 New (year to 2026):
• Healthspan VC ~2.3x in 2025 — SVB: mostly a few megadeals
• Flagships dominate: Altos, Retro, NewLimit
• 2026: Life Biosciences ER-100 (partial OSK) entered human dosing
• Calico fosigotifator fail (2025) + AbbVie exit — big checks ≠ proof
Caveat: money is concentrated, not absent. Missing: a broad pipeline through failure, biomarkers, human outcomes.
Longevity.Technology
DNA risk map → TellMeGen
NFX Bio / Longevity.Technology: science is at an inflection — reprogramming, organs, delivery, AI discovery, diagnostics. Tech tree mapped. Capital is not.
Aging is the #1 disease risk factor, yet under 0.5% of NIH funding. Many ultra-wealthy stay away: burned by clinics, doubt aging is fixable, assume wealth buys the cure later, or fear looking vain.
🟢 New (year to 2026):
• Healthspan VC ~2.3x in 2025 — SVB: mostly a few megadeals
• Flagships dominate: Altos, Retro, NewLimit
• 2026: Life Biosciences ER-100 (partial OSK) entered human dosing
• Calico fosigotifator fail (2025) + AbbVie exit — big checks ≠ proof
Caveat: money is concentrated, not absent. Missing: a broad pipeline through failure, biomarkers, human outcomes.
Longevity.Technology
DNA risk map → TellMeGen
Your organs don’t age as one clock — and the immune system may lead the pack.
Nature Communications (9 Sep 2026) — plasma proteomes from 53,014 UK Biobank people → 16 organ/system aging clocks. Validated in China Kadoorie Biobank (n=3,977).
What jumped out:
🟢 5,436 links to 1,059 diseases — organ-specific and pan-organ patterns
🟢 clocks react across 841 environmental factors
🟢 genetics: 261 loci; immune + liver are the most connected hubs
🟣 longitudinal network (n=1,006): immune, liver, stomach show temporal precedence (artery stronger in ♀, stomach in ♂)
Caveats:
🟠 clocks from blood proteins — not a biopsy of every organ
🟠 “precedence” is statistical, not proof of causation
🟠 atlas ≠ a therapy you can take tonight
🗒 Aging is a network of organs, not one birthday. The next geroprotectors may need organ-level targets — not just “biological age.”
Source: Nat Commun 2026 · DOI 10.1038/s41467-026-77365-8
Nature Communications (9 Sep 2026) — plasma proteomes from 53,014 UK Biobank people → 16 organ/system aging clocks. Validated in China Kadoorie Biobank (n=3,977).
What jumped out:
🟢 5,436 links to 1,059 diseases — organ-specific and pan-organ patterns
🟢 clocks react across 841 environmental factors
🟢 genetics: 261 loci; immune + liver are the most connected hubs
🟣 longitudinal network (n=1,006): immune, liver, stomach show temporal precedence (artery stronger in ♀, stomach in ♂)
Caveats:
🟠 clocks from blood proteins — not a biopsy of every organ
🟠 “precedence” is statistical, not proof of causation
🟠 atlas ≠ a therapy you can take tonight
🗒 Aging is a network of organs, not one birthday. The next geroprotectors may need organ-level targets — not just “biological age.”
Source: Nat Commun 2026 · DOI 10.1038/s41467-026-77365-8
Danshen's phenolic acids just cleared zombie cells — and old mice lived longer.
npj Aging (11 Sep 2026) — Zhang / Sun / Kirkland: salvianolic acids A, B, E from Salvia miltiorrhiza, screened from 55 natural agents.
What's new:
🟢 selective kill of senescent cells across lineages
🟢 hit GSTP1 (redox shield) → ROS surge → apoptosis + ferroptosis
🟢 biweekly SAA from 24–27 mo (~human 75–90): +51% median remaining life / +11% overall lifespan; mortality hazard −68%
🟣 better grip, walking, endurance — without a longer sick stretch at the end
Caveats:
🟠 mice + intermittent i.p. — not your herbal tea
🟠 oral bioavailability of SAs is notoriously poor
🟠 still needs independent replication before hype
🗒 Late-life senolysis that works when started “old” is the rare punchline. Danshen capsules ≠ this protocol.
AgePilot — habits that move the healthspan dial → t.me/AgePilotBot
Source: Zhang et al., npj Aging 2026 · DOI 10.1038/s41514-026-00496-1
npj Aging (11 Sep 2026) — Zhang / Sun / Kirkland: salvianolic acids A, B, E from Salvia miltiorrhiza, screened from 55 natural agents.
What's new:
🟢 selective kill of senescent cells across lineages
🟢 hit GSTP1 (redox shield) → ROS surge → apoptosis + ferroptosis
🟢 biweekly SAA from 24–27 mo (~human 75–90): +51% median remaining life / +11% overall lifespan; mortality hazard −68%
🟣 better grip, walking, endurance — without a longer sick stretch at the end
Caveats:
🟠 mice + intermittent i.p. — not your herbal tea
🟠 oral bioavailability of SAs is notoriously poor
🟠 still needs independent replication before hype
🗒 Late-life senolysis that works when started “old” is the rare punchline. Danshen capsules ≠ this protocol.
AgePilot — habits that move the healthspan dial → t.me/AgePilotBot
Source: Zhang et al., npj Aging 2026 · DOI 10.1038/s41514-026-00496-1
Your voice just became a biological clock — in 30 seconds.
npj Aging (11 Sep 2026) — Krongauz / Segal: “Voice Age” from a short speech clip in 6,979 adults (40–70, Hebrew-speaking).
What's new:
🟢 sex-stratified models on WavLM-Large embeddings
🟢 women: R² 53.9%, MAE ~4.0 y · men: R² 44.0%, MAE ~4.4 y
🟢 #2 of 9 single-modality age models — only partly overlaps DNA/imaging/lifestyle clocks
🟣 stacking Voice Age onto other clocks always helped; + metabolomics → R² up to 65% (♀)
🟣 “Voice Age acceleration” tracked adiposity, sleep apnea signals, liver imaging
Caveats:
🟠 one language / one country / ages 40–70
🟠 predicts chronological age well — not yet proven as an intervention endpoint
🟠 mic quality, accent, illness can shift the score
🗒 Longevity needs cheap, frequent readouts. If a phone clip carries independent aging signal, that’s a new sensor class — not a magic mirror.
Source: Krongauz et al., npj Aging 2026 · DOI 10.1038/s41514-026-00519-x
npj Aging (11 Sep 2026) — Krongauz / Segal: “Voice Age” from a short speech clip in 6,979 adults (40–70, Hebrew-speaking).
What's new:
🟢 sex-stratified models on WavLM-Large embeddings
🟢 women: R² 53.9%, MAE ~4.0 y · men: R² 44.0%, MAE ~4.4 y
🟢 #2 of 9 single-modality age models — only partly overlaps DNA/imaging/lifestyle clocks
🟣 stacking Voice Age onto other clocks always helped; + metabolomics → R² up to 65% (♀)
🟣 “Voice Age acceleration” tracked adiposity, sleep apnea signals, liver imaging
Caveats:
🟠 one language / one country / ages 40–70
🟠 predicts chronological age well — not yet proven as an intervention endpoint
🟠 mic quality, accent, illness can shift the score
🗒 Longevity needs cheap, frequent readouts. If a phone clip carries independent aging signal, that’s a new sensor class — not a magic mirror.
Source: Krongauz et al., npj Aging 2026 · DOI 10.1038/s41514-026-00519-x
There’s a chance to minimize the catastrophe.
Amodei’s We Must Pace the Frontier: not a halt — a brake so safety keeps up. Longevity upside depends on it.
AI can crush drug discovery, aging clocks, personalized medicine. Lose a decade to a misaligned swarm or panic politics — and that upside slips.
🟢 RSI already speeds model→model progress
🟢 HF swarm = warning (Dario: 6–12 mo to catastrophic cyber scale if we keep racing)
🟢 Asks: embedded independent evaluators · pre-release gates · democratic coordination
Can’t stop progress. Can refuse reckless release.
Essay
DNA risk map → TellMeGen
Amodei’s We Must Pace the Frontier: not a halt — a brake so safety keeps up. Longevity upside depends on it.
AI can crush drug discovery, aging clocks, personalized medicine. Lose a decade to a misaligned swarm or panic politics — and that upside slips.
🟢 RSI already speeds model→model progress
🟢 HF swarm = warning (Dario: 6–12 mo to catastrophic cyber scale if we keep racing)
🟢 Asks: embedded independent evaluators · pre-release gates · democratic coordination
Can’t stop progress. Can refuse reckless release.
Essay
DNA risk map → TellMeGen
Which aging clocks actually move when you intervene?
Nature Medicine — Sehgal / Higgins-Chen (Yale + TruDiagnostic): TranslAGE harmonizes 51 human longevity trials and scores the same 16 epigenetic clocks (+94 other DNAm markers) on every study.
What's new:
🟢 mortality / pace clocks (esp. DunedinPACE, PCGrimAge) respond most — not Horvath-style chrono clocks
🟢 pharma + lifestyle beat supplements / procedures on average
🟢 anti-TNF + Mediterranean diet: most reproducible across studies
🟢 senolytic epigenetic signals look inconsistent study-to-study
🟢 bigger shifts in disease cohorts than healthy ones
Caveat: clock movement ≠ proven healthspan or lifespan gain. Responsiveness is a prerequisite for surrogate endpoints — not the surrogate itself.
🗒 Takeaway: for trial design, prioritize reliable Gen2+ clocks — and match the clock to the intervention class.
Nature Medicine — Sehgal / Higgins-Chen (Yale + TruDiagnostic): TranslAGE harmonizes 51 human longevity trials and scores the same 16 epigenetic clocks (+94 other DNAm markers) on every study.
What's new:
🟢 mortality / pace clocks (esp. DunedinPACE, PCGrimAge) respond most — not Horvath-style chrono clocks
🟢 pharma + lifestyle beat supplements / procedures on average
🟢 anti-TNF + Mediterranean diet: most reproducible across studies
🟢 senolytic epigenetic signals look inconsistent study-to-study
🟢 bigger shifts in disease cohorts than healthy ones
Caveat: clock movement ≠ proven healthspan or lifespan gain. Responsiveness is a prerequisite for surrogate endpoints — not the surrogate itself.
🗒 Takeaway: for trial design, prioritize reliable Gen2+ clocks — and match the clock to the intervention class.
APOE4 doesn't just float amyloid — it floods the blood–brain barrier with fibronectin.
Nature Aging (11 Sep 2026) — Columbia: why ε4 carriers get early BBB leak — and how rare FN1 protection may blunt it (~71% lower AD risk in prior genetics).
What's new:
🟢 astrocytes dump excess fibronectin (FN1) around vessels under APOE4 + Aβ42 + inflammation
🟢 FN1 alone is enough to break the barrier (integrin → FAK → VEGF / HB-EGF / IGF-1 collapses)
🟢 APOE4 mice: ~2× brain fibronectin vs APOE3 + leaky barrier
🟢 cut FN1 or restore growth-factor signaling → BBB returns (cells, fish, mice)
🟣 human brains + CSF: high FN1 tracks inflamed astrocytes
Caveats:
🟠 mechanism paper — not a drug trial
🟠 FN1 also heals wounds; blanket blockade could bite
🗒 Brain aging may be as much vascular-interface as plaque — FN1 is now a concrete dial.
AgePilot — habits that move healthspan → t.me/AgePilotBot
Nature Aging (11 Sep 2026) — Columbia: why ε4 carriers get early BBB leak — and how rare FN1 protection may blunt it (~71% lower AD risk in prior genetics).
What's new:
🟢 astrocytes dump excess fibronectin (FN1) around vessels under APOE4 + Aβ42 + inflammation
🟢 FN1 alone is enough to break the barrier (integrin → FAK → VEGF / HB-EGF / IGF-1 collapses)
🟢 APOE4 mice: ~2× brain fibronectin vs APOE3 + leaky barrier
🟢 cut FN1 or restore growth-factor signaling → BBB returns (cells, fish, mice)
🟣 human brains + CSF: high FN1 tracks inflamed astrocytes
Caveats:
🟠 mechanism paper — not a drug trial
🟠 FN1 also heals wounds; blanket blockade could bite
🗒 Brain aging may be as much vascular-interface as plaque — FN1 is now a concrete dial.
AgePilot — habits that move healthspan → t.me/AgePilotBot
👏1
Senescent cells need mitochondrial citrate to scream inflammation — cut the export, quiet the SASP.
Nature — Martini et al.: zombie cells keep the cycle-arrest program, but their inflammatory shout runs on a metabolic–epigenetic checkpoint.
What's new:
🟢 senescent cells ramp the pyruvate → citrate → acetyl-CoA axis
🟢 SLC25A1 exports citrate; ACLY makes acetyl-CoA for histone marks at SASP genes
🟢 mtDNA / cGAS–STING lights the fuse — acetyl-CoA lets transcription actually fire
🟢 CTPI2 (SLC25A1 block): SASP down, p16/p21 arrest stays
🟢 aged mice: less SASP chromatin access, less inflammation, delayed frailty, better strength
Caveats:
🟠 mice + cells — not a human trial
🟠 senomorphic (mute the shout), not senolytic (kill the cell)
🗒 You may not need to erase every senescent cell — starve the inflammatory license instead.
Nature — Martini et al.: zombie cells keep the cycle-arrest program, but their inflammatory shout runs on a metabolic–epigenetic checkpoint.
What's new:
🟢 senescent cells ramp the pyruvate → citrate → acetyl-CoA axis
🟢 SLC25A1 exports citrate; ACLY makes acetyl-CoA for histone marks at SASP genes
🟢 mtDNA / cGAS–STING lights the fuse — acetyl-CoA lets transcription actually fire
🟢 CTPI2 (SLC25A1 block): SASP down, p16/p21 arrest stays
🟢 aged mice: less SASP chromatin access, less inflammation, delayed frailty, better strength
Caveats:
🟠 mice + cells — not a human trial
🟠 senomorphic (mute the shout), not senolytic (kill the cell)
🗒 You may not need to erase every senescent cell — starve the inflammatory license instead.
🔥1